Inhaled KB707 Plus Pembrolizumab in Lung Cancer

Patients with advanced lung cancer often experience disease progression despite treatment with immune checkpoint inhibitors. In this episode of Cancer Advances, Wen Wee Ma, MBBS, discusses data evaluating inhaled KB707, a modified herpes simplex virus designed to locally deliver IL-2 and IL-12, in combination with pembrolizumab. Dr. Ma reviews the rationale behind this novel immunotherapy approach, early efficacy and safety findings and the potential role of inhaled therapies in future lung cancer treatment strategies.